Q-omics provides the consensus-scored LY6E-DT profile across patient tissues and cancer cell-line models. LY6E-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LY6E-DT is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LY6E-DT RNA expression shows 14,573 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where LY6E-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LY6E-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LY6E-DT survival associations across molecular data types. LY6E-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LY6E-DT RNA expression–survival associations across cancer types. High LY6E-DT expression shows unfavorable associations in KIRP, PAAD, GBM and UCS, but favorable associations in KIRC and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LY6E-DT RNA expression.
This table summarizes LY6E-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LY6E-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LY6E-DT shows lower tumor expression in KICH, LIHC and CHOL and higher tumor expression in KIRC, THCA and COAD. The KIRC box plot shows higher LY6E-DT RNA expression in tumor versus normal tissue (log2 FC = +1.352, t-test p < 0.001).
This table shows molecular features associated with LY6E-DT in patient tissues and cancer cell lines. In patient samples, LY6E-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
